Development of a novel plaque reduction neutralisation test for hantavirus infection

Mem Inst Oswaldo Cruz. 2015 Aug;110(5):624-8. doi: 10.1590/0074-02760150102. Epub 2015 Jun 30.

Abstract

In the Americas, hantaviruses cause severe cardiopulmonary syndrome (HCPS) with a high fatality rate. Hantavirus infection is commonly diagnosed using serologic techniques and reverse transcription-polymerase chain reaction. This paper presents a novel plaque reduction neutralisation test (PRNT) for detecting antibodies to Brazilian hantavirus. Using PRNT, plaque detection was enhanced by adding 0.6% of dimethyl sulfoxide into the overlay culture medium of the infected cells. This procedure facilitated clear visualisation of small plaques under the microscope and provided for easy and accurate plaque counting. The sera from 37 HCPS patients from the city of Ribeirão Preto, Brazil was evaluated for the Rio Mamoré virus (RIOMV) using PRNT. Six samples exhibited neutralising antibodies; these antibodies exhibited a low titre. The low level of seropositive samples may be due to fewer cross-reactions between two different hantavirus species; the patients were likely infected by Araraquara virus (a virus that has not been isolated) and RIOMV was used for the test. This assay offers a new approach to evaluating and measuring neutralising antibodies produced during hantavirus infections and it can be adapted to other hantaviruses, including viruses that will be isolated in the future.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Viral / blood*
  • Antibodies, Viral / immunology
  • Enzyme-Linked Immunosorbent Assay
  • Hantavirus Pulmonary Syndrome / diagnosis*
  • Hantavirus Pulmonary Syndrome / virology
  • Humans
  • Neutralization Tests / methods*
  • Orthohantavirus / growth & development
  • Orthohantavirus / immunology
  • Reverse Transcriptase Polymerase Chain Reaction
  • Sensitivity and Specificity
  • Viral Plaque Assay

Substances

  • Antibodies, Viral

Grants and funding

Financial support: FAPESP (08/50617-6; scholarships 11/16866-1, 11/05067-0, 12/24150-9), CNPq (301677/2013-1)